Skip to content
10-Q

Quarterly Report

Eloxx Pharmaceuticals, Inc. ELOX

0001193125-26-204722

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 7.57M sh
Shares Diluted Q1 2026 · Mar 31, 2026 48.21M sh
Shares Diluted Q1 2026 · Mar 31, 2025 3.81M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$5.45M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $1.2M
Short Term Debt Q1 2026 · Mar 31, 2026 $0
Short Term Debt Q1 2026 · Dec 31, 2025 $1M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $6.36M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $4.79M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $450K
Stockholders Equity Q1 2026 · Mar 31, 2026 −$7.58M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$11.91M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$26.02M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$24.34M
Current Liabilities Q1 2026 · Mar 31, 2026 $16.09M
Current Liabilities Q1 2026 · Dec 31, 2025 $17.18M
Current Assets Q1 2026 · Mar 31, 2026 $8.5M
Current Assets Q1 2026 · Dec 31, 2025 $5.27M
Total Assets Q1 2026 · Mar 31, 2026 $8.5M
Total Assets Q1 2026 · Dec 31, 2025 $5.27M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.08
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.45
Eps Basic Q1 2026 · Mar 31, 2026 −$0.08
Eps Basic Q1 2026 · Mar 31, 2025 −$0.45
Sga Expense Q1 2026 · Mar 31, 2026 $2.14M
Sga Expense Q1 2026 · Mar 31, 2025 $712K
Net Income Q1 2026 · Mar 31, 2026 −$3.75M
Net Income Q1 2026 · Mar 31, 2025 −$1.71M
Operating Income Q1 2026 · Mar 31, 2026 −$3.8M
Operating Income Q1 2026 · Mar 31, 2025 −$1.22M